Recent Updates
Recently added Catalysts
CRMD Positive Sentiment Score: 65/100

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

Wednesday, August 7, 2024 1 min read
Key Takeaway: CorMedix Inc. plans to report its financial results for the second quarter of 2024 on August 14, 2024. The company will also host a conference call to provide a corporate update. Recently, CorMedix launched its lead product, DefenCath, which received FDA approval in November 2023 and is aimed at life-threatening conditions. The dual launch in inpatient and outpatient settings reflects advancements in their commercialization strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • CorMedix is scheduled to report its Q2 2024 financial results, indicating progress in its operations.
  • The launch of DefenCath in both inpatient and outpatient settings highlights successful commercialization.
  • The FDA approval of DefenCath suggests a positive regulatory outlook for the company.

Full Press Release Details

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
Wednesday, August 14th @ 8:30am ET
Domestic: 1-877-270-2148
International: 1-412-902-6510
Webcast: Webcast Link
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
daniel@lifesciadvisors.com

Frequently Asked Questions

When will CorMedix report its Q2 financial results?

CorMedix will announce its Q2 financial results on August 14, 2024.

What time is CorMedix's corporate update conference call?

The conference call is scheduled for 8:30 AM Eastern Time on August 14, 2024.

What is CorMedix's lead product?

CorMedix's lead product is DefenCath®, approved by the FDA on November 15, 2023.

When was DefenCath launched commercially?

DefenCath was launched in inpatient settings in April 2024 and outpatient settings in July 2024.

What are CorMedix's future plans for DefenCath?

CorMedix aims to develop DefenCath as a catheter lock solution for various patient populations.

Tags: CRMD Viatris Investor Conferences Healthcare CorMedix DefenCath Q2 2024 FDA approval biopharmaceutical
Last updated: Aug 7, 2024